Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Informatics » CHOP Team Develops Computational Model to Predict Effects of Alternative Splicing

CHOP Team Develops Computational Model to Predict Effects of Alternative Splicing

Apr 05, 2019
|
Uduak Grace Thomas
Premium

NEW YORK (GenomeWeb) — Researchers from Children's Hospital of Philadelphia (CHOP) have developed a computational tool that uses deep-learning techniques to detect the different ways RNA is spliced when it is copied from DNA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

UK Funds Challenge Trial

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

Watching the Changes

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Max Planck, Nature Strike a Deal

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

PNAS Papers on Ancient Tibetan Animals, HNSCC Drug Response, More

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.

Oct
21
Featured Webinar

Target Enrichment NGS Panel Outperforms the Gold Standard for Sequence and CNV Analysis

Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.

Oct
26
Featured Webinar

Robust CNV Detection Using Whole-Exome Sequencing for Complex Cases

Sponsored by
Sophia Genetics

This webinar will discuss Genotypos Science Labs’ experience with a whole-exome sequencing solution supporting the detection of copy number variants (CNVs) for the management of complex cases.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Oct
28
Featured Webinar

How Low Can You Go? Reduce Breeding Costs with an Optimized Genotyping and Analysis Strategy

Sponsored by
NRGene

Molecular breeding methods such as genomic selection and genome-wide association studies often require high-density genotypic data from many samples, but the cost and complexity of genotyping at this scale may be prohibitive.

What's Popular?

In Informatics

  1. Tempus Enters Infectious Disease Market With Large-Scale COVID-19 Testing, Data Initiative

    Premium

  2. Pacific Biosciences, Children's Mercy, Microsoft Collaborate on Rare Genetic Disease Diagnostics

  3. Imec Adds Variant Calling to DNA Analytics Software to Accelerate Genome Analysis

    Premium

  4. NRGene, Agriplex to Offer Mid-Density Genotyping Services

  5. NIH Kicks Off Second Stage of 4D Nucleome Program With $142M in Research Grants

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.